258 related articles for article (PubMed ID: 31977001)
1. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
3. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
4. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
5. Pegasparaginase: where do we stand?
Zeidan A; Wang ES; Wetzler M
Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697
[TBL] [Abstract][Full Text] [Related]
6. Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action.
Buhtoiarov IN; Zembillas AS
Pediatr Blood Cancer; 2021 Mar; 68(3):e28743. PubMed ID: 33009863
[No Abstract] [Full Text] [Related]
7. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
8. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Tong WH; van der Sluis IM; Alleman CJ; van Litsenburg RR; Kaspers GJ; Pieters R; Uyl-de Groot CA
Haematologica; 2013 May; 98(5):753-9. PubMed ID: 23403311
[TBL] [Abstract][Full Text] [Related]
9. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
10. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Stock W; Douer D; DeAngelo DJ; Arellano M; Advani A; Damon L; Kovacsovics T; Litzow M; Rytting M; Borthakur G; Bleyer A
Leuk Lymphoma; 2011 Dec; 52(12):2237-53. PubMed ID: 21827361
[TBL] [Abstract][Full Text] [Related]
11. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
12. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
Kloos R; van der Sluis IM; Mastrobattista E; Hennink W; Pieters R; Verhoef JJ
Br J Haematol; 2020 May; 189(3):442-451. PubMed ID: 31883112
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
14. Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.
Riley DO; Schlefman JM; Vitzthum Von Eckstaedt V HC; Morris AL; Keng MK; El Chaer F
Curr Hematol Malig Rep; 2021 Jun; 16(3):314-324. PubMed ID: 33978914
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.
Aldoss I; Pourhassan H; Douer D
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):787-794. PubMed ID: 36114134
[TBL] [Abstract][Full Text] [Related]
16. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
18. Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.
Brigitha LJ; Pieters R; Struys EA; Bakkali A; van der Sluis IM
Pediatr Blood Cancer; 2022 Nov; 69(11):e29865. PubMed ID: 35880973
[TBL] [Abstract][Full Text] [Related]
19. L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
Alshiekh-Nasany R; Douer D
Acta Haematol; 2016; 135(4):208-10. PubMed ID: 26841296
[TBL] [Abstract][Full Text] [Related]
20. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]